Emily R. Frost
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emily R. Frost has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Robert Bruce Gilchrist
Fertility & Research Centre, Discipline of Women’s Health, School of Clinical Medicine, University of New South Wales Sydney, Australia
6 shared publications - Bettina P. Mihalas
Fertility & Research Centre, Discipline of Women’s Health, School of Clinical Medicine, University of New South Wales Sydney , Sydney, NSW
5 shared publications - Jessie. M. Sutherland
College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, Australia
5 shared publications - Irene E. Sucquart
Fertility & Research Centre, Discipline of Women’s Health, School of Clinical Medicine, University of New South Wales Sydney , Sydney, NSW
3 shared publications - Lindsay E. Wu
UNSW Sydney
3 shared publications - Robin Lovell-Badge
Laboratory of Stem Cell Biology and Developmental Genetics, The Francis Crick Institute, London NW1 1AT, UK
3 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (10) , 1741-1761
A proteomic signature of oocyte quality from models of varying oocyte developmental competence
STUDY QUESTION: Which proteins underpin oocyte developmental competence, as modelled by oocytes of variable competence matured in vivo or matured in vitro under different conditions (capacitation in vitro maturation (CAPA-IVM) or standard IVM)? SUMMARY ANSWER: Significant differences in the global proteome were observed in both oocytes and their corresponding cumulus cells depending on the mode of oocyte maturation, with key variations in eukaryotic translation, autophagy, and endocytosis pathways within oocytes, and changes in reactive oxygen species detoxification and serine biosynthesis in cumulus cells. WHAT IS KNOWN ALREADY: Within the ovarian follicle, mammalian oocytes must acquire the necessary molecular machinery to support successful fertilization and embryonic development. Close contact with the surrounding cumulus cells ensures coordinated nuclear and cytoplasmic maturation of the oocyte, along with the accumulation of proteins stored within the oocyte in cytoplasmic lattices and endo-lysosomal vesicular assemblies. STUDY DESIGN, SIZE, DURATION: This basic science study utilized a mouse model to assess proteomic changes across three oocyte competence models. Key proteins identified in mouse oocytes were also assessed in discarded immature human germinal vesicle (GV) oocytes and MII oocytes following rescue-IVM. Three oocyte maturation methods were tested: (i) in vivo maturation, (ii) CAPA-IVM, and (iii) standard IVM. In vivo maturation served as a positive control group, whereby metaphase II (MII) mature oocytes were collected from mice stimulated with pregnant mare serum gonadotropin (PMSG) and triggered with hCG, simulating full ovarian stimulation. For the IVM groups, immature cumulus–oocyte complexes (COCs) were collected from mildly stimulated (23 h PMSG) mice. For the standard IVM group, immature COCs were matured in media containing amphiregulin and epiregulin for 18 h. For the CAPA group, COCs were held for 24 h in pre-IVM conditions in the presence of c-type natriuretic peptide (CNP), oestradiol, insulin, and FSH, and then matured via IVM in media containing FSH, amphiregulin, and epiregulin. Four biological replicates were performed for mouse proteomics experiments; three biological replicates were performed for mouse immunocytochemistry experiments; and six replicates were performed for embryology experiments. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Four- to six-week-old C57BL/6JAusb mice were used for all mouse experiments. Embryology outcomes were used to confirm the variation in oocyte developmental competence between the three maturation groups. For the in vivo, CAPA and IVM groups, mature MII COCs were collected and separated into oocytes and cumulus cells. Oocytes and cumulus cells were subjected to mass spectrometry and bioinformatic analysis was performed using Proteome Discoverer and Ingenuity Pathway Analysis, with data validated by immunofluorescence. To assess conservation of proteins in human oocytes, 49 oocytes were collected from 36 patients following ART cycles and subject to immunofluorescence. Rescue-IVM was also performed with half of the human oocyte cohort to obtain MII oocytes. MAIN RESULTS AND THE ROLE OF CHANCE: Proteomic profiling (at least two peptides per protein) identified around 1600 proteins in mouse oocytes and 3100 proteins in mouse cumulus cells across all three treatment groups. Differential expression analysis and pattern analysis collectively revealed a signature of proteins that were consistently differentially expressed between in vivo and in vitro oocyte maturation systems (log2FC of ± 1 and a P-value ≤ 0.05). These subsets of proteins were mapped to biological processes including eukaryotic translation, autophagy, and endocytosis pathways within oocytes. Orthogonal validation of clathrin, ribosomal protein L24, and eukaryotic initiation factor 2A supported the proteomic findings, and their expression was conserved in human GV and MII oocytes. Changes in reactive oxygen species detoxification and serine biosynthesis were observed in mouse cumulus cells, with fluorescence intensity changes in ferredoxin-1 and phosphoglycerate dehydrogenase supporting the dysregulation of cumulus cell processes during IVM. LARGE SCALE DATA: The mass spectrometry data are available via ProteomeXchange with identifier PXD073269. LIMITATIONS, REASONS FOR CAUTION: The foundational mechanisms of oocyte developmental competence remain elusive, particularly in humans where MII oocytes are heterogenous in quality within the same stimulation cycle and patient. Limitations in this study include the detection and proteome coverage of poorly expressed proteins, the inability to check molecular conservation in human CAPA-IVM and IVM oocytes, the use of fetuin in the mouse in vitro systems, and the potential source of keratin proteins in oocyte samples, and these factors must all be carefully considered. C57Bl6/J mice were used as the model species, allowing precise control over differing models of oocyte quality and capacity to analyse large numbers of oocytes. However, care is required when interpreting the significance of these findings in mice to mechanisms regulating human oocyte quality. Nonetheless, the in vivo stimulation and both IVM protocols used in this study are clinically relevant and developmentally matched. This study has also not addressed oocyte developmental competence in gonadotropin-free IVM oocytes, which is now a clinical reality. WIDER IMPLICATIONS OF THE FINDINGS: This study adds to the wider literature indicating that oocytes matured in vitro, either through CAPA-IVM or IVM, are unable to achieve the developmental competence rates observed with in vivo stimulation. Through examination of the global proteome in oocytes, molecular pathways including eukaryotic translation, autophagy, and endocytosis were dysregulated in in vitro oocytes. Recent findings have revealed the critical role of these pathways to...
- 20 August 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (10) , 1741-1761
Open AccessA proteomic signature of oocyte quality from models of varying oocyte developmental competence
STUDY QUESTION: Which proteins underpin oocyte developmental competence, as modelled by oocytes of variable competence matured in vivo or matured in vitro under different conditions (capacitation in vitro maturation (CAPA-IVM) or standard IVM)? SUMMARY ANSWER: Significant differences in the global proteome were observed in both oocytes and their corresponding cumulus cells depending on the mode of oocyte maturation, with key variations in eukaryotic translation, autophagy, and endocytosis pathways within oocytes, and changes in reactive oxygen species detoxification and serine biosynthesis in cumulus cells. WHAT IS KNOWN ALREADY: Within the ovarian follicle, mammalian oocytes must acquire the necessary molecular machinery to support successful fertilization and embryonic development. Close contact with the surrounding cumulus cells ensures coordinated nuclear and cytoplasmic maturation of the oocyte, along with the accumulation of proteins stored within the oocyte in cytoplasmic lattices and endo-lysosomal vesicular assemblies. STUDY DESIGN, SIZE, DURATION: This basic science study utilized a mouse model to assess proteomic changes across three oocyte competence models. Key proteins identified in mouse oocytes were also assessed in discarded immature human germinal vesicle (GV) oocytes and MII oocytes following rescue-IVM. Three oocyte maturation methods were tested: (i) in vivo maturation, (ii) CAPA-IVM, and (iii) standard IVM. In vivo maturation served as a positive control group, whereby metaphase II (MII) mature oocytes were collected from mice stimulated with pregnant mare serum gonadotropin (PMSG) and triggered with hCG, simulating full ovarian stimulation. For the IVM groups, immature cumulus–oocyte complexes (COCs) were collected from mildly stimulated (23 h PMSG) mice. For the standard IVM group, immature COCs were matured in media containing amphiregulin and epiregulin for 18 h. For the CAPA group, COCs were held for 24 h in pre-IVM conditions in the presence of c-type natriuretic peptide (CNP), oestradiol, insulin, and FSH, and then matured via IVM in media containing FSH, amphiregulin, and epiregulin. Four biological replicates were performed for mouse proteomics experiments; three biological replicates were performed for mouse immunocytochemistry experiments; and six replicates were performed for embryology experiments. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Four- to six-week-old C57BL/6JAusb mice were used for all mouse experiments. Embryology outcomes were used to confirm the variation in oocyte developmental competence between the three maturation groups. For the in vivo, CAPA and IVM groups, mature MII COCs were collected and separated into oocytes and cumulus cells. Oocytes and cumulus cells were subjected to mass spectrometry and bioinformatic analysis was performed using Proteome Discoverer and Ingenuity Pathway Analysis, with data validated by immunofluorescence. To assess conservation of proteins in human oocytes, 49 oocytes were collected from 36 patients following ART cycles and subject to immunofluorescence. Rescue-IVM was also performed with half of the human oocyte cohort to obtain MII oocytes. MAIN RESULTS AND THE ROLE OF CHANCE: Proteomic profiling (at least two peptides per protein) identified around 1600 proteins in mouse oocytes and 3100 proteins in mouse cumulus cells across all three treatment groups. Differential expression analysis and pattern analysis collectively revealed a signature of proteins that were consistently differentially expressed between in vivo and in vitro oocyte maturation systems (log2FC of ± 1 and a P-value ≤ 0.05). These subsets of proteins were mapped to biological processes including eukaryotic translation, autophagy, and endocytosis pathways within oocytes. Orthogonal validation of clathrin, ribosomal protein L24, and eukaryotic initiation factor 2A supported the proteomic findings, and their expression was conserved in human GV and MII oocytes. Changes in reactive oxygen species detoxification and serine biosynthesis were observed in mouse cumulus cells, with fluorescence intensity changes in ferredoxin-1 and phosphoglycerate dehydrogenase supporting the dysregulation of cumulus cell processes during IVM. LARGE SCALE DATA: The mass spectrometry data are available via ProteomeXchange with identifier PXD073269. LIMITATIONS, REASONS FOR CAUTION: The foundational mechanisms of oocyte developmental competence remain elusive, particularly in humans where MII oocytes are heterogenous in quality within the same stimulation cycle and patient. Limitations in this study include the detection and proteome coverage of poorly expressed proteins, the inability to check molecular conservation in human CAPA-IVM and IVM oocytes, the use of fetuin in the mouse in vitro systems, and the potential source of keratin proteins in oocyte samples, and these factors must all be carefully considered. C57Bl6/J mice were used as the model species, allowing precise control over differing models of oocyte quality and capacity to analyse large numbers of oocytes. However, care is required when interpreting the significance of these findings in mice to mechanisms regulating human oocyte quality. Nonetheless, the in vivo stimulation and both IVM protocols used in this study are clinically relevant and developmentally matched. This study has also not addressed oocyte developmental competence in gonadotropin-free IVM oocytes, which is now a clinical reality. WIDER IMPLICATIONS OF THE FINDINGS: This study adds to the wider literature indicating that oocytes matured in vitro, either through CAPA-IVM or IVM, are unable to achieve the developmental competence rates observed with in vivo stimulation. Through examination of the global proteome in oocytes, molecular pathways including eukaryotic translation, autophagy, and endocytosis were dysregulated in in vitro oocytes. Recent findings have revealed the critical role of these pathways to...
- Open Access
Aging disrupts cumulus–oocyte NAD⁺ homeostasis
The age-related decline in oocyte nicotinamide adenine dinucleotide (NAD⁺) is associated with reduced developmental potential and female infertility. Despite the extraordinary longevity of the female germline, the mechanism for maintaining oocyte NAD⁺ remains unresolved. Here, we used stable isotope tracing to identify a new mechanism for shared, intercellular NAD ⁺ biosynthesis, whereby somatic–germline metabolic coupling between the oocyte and its surrounding cumulus cells is critical to maintain oocyte NAD ⁺ homeostasis. We show that this coupling deteriorates with reproductive aging, identifying altered NAD⁺ metabolism in cumulus cells from mice and women of advancing reproductive age. This cumulus–oocyte metabolic coupling of NAD⁺ biosynthesis contributes to protection against the age-related increases in oocyte reactive oxygen species (ROS). In intact complexes, restoring NAD⁺ through supplementation with the precursor nicotinamide mononucleotide (NMN) increased glutathione, reduced ROS and improved mitochondrial membrane potential in oocytes from aged mice and in oocytes exposed to oxidative insult. Importantly, the ability of NMN to resolve elevated ROS depends on the presence of cumulus cells. Together, this new model of somatic-germline metabolic coupling of NAD ⁺ biosynthesis places an age-related deterioration in cumulus cell-mediated metabolic support as a key driver of impaired oocyte NAD ⁺ levels and redox dysregulation with aging.
Open AccessAging disrupts cumulus–oocyte NAD⁺ homeostasis
The age-related decline in oocyte nicotinamide adenine dinucleotide (NAD⁺) is associated with reduced developmental potential and female infertility. Despite the extraordinary longevity of the female germline, the mechanism for maintaining oocyte NAD⁺ remains unresolved. Here, we used stable isotope tracing to identify a new mechanism for shared, intercellular NAD ⁺ biosynthesis, whereby somatic–germline metabolic coupling between the oocyte and its surrounding cumulus cells is critical to maintain oocyte NAD ⁺ homeostasis. We show that this coupling deteriorates with reproductive aging, identifying altered NAD⁺ metabolism in cumulus cells from mice and women of advancing reproductive age. This cumulus–oocyte metabolic coupling of NAD⁺ biosynthesis contributes to protection against the age-related increases in oocyte reactive oxygen species (ROS). In intact complexes, restoring NAD⁺ through supplementation with the precursor nicotinamide mononucleotide (NMN) increased glutathione, reduced ROS and improved mitochondrial membrane potential in oocytes from aged mice and in oocytes exposed to oxidative insult. Importantly, the ability of NMN to resolve elevated ROS depends on the presence of cumulus cells. Together, this new model of somatic-germline metabolic coupling of NAD ⁺ biosynthesis places an age-related deterioration in cumulus cell-mediated metabolic support as a key driver of impaired oocyte NAD ⁺ levels and redox dysregulation with aging.
- Open Access
A proteomic signature of oocyte quality from models of varying oocyte developmental competence
Study question: Which proteins underpin oocyte developmental competence, as modelled by oocytes of variable competence matured in vivo , or matured in vitro under different conditions (capacitation in vitro maturation (CAPA) or standard in vitro maturation (IVM))? Summary answer: Significant differences in the global proteome were observed in both oocytes and their corresponding cumulus cells depending on the mode of oocyte maturation, with key variations in eukaryotic translation, autophagy and endocytosis pathways within oocytes, and changes in reactive oxygen species detoxification and serine biosynthesis in cumulus cells. What is known already: Within the ovarian follicle, mammalian oocytes must acquire the necessary molecular machinery to support successful fertilisation and embryonic development. Close contact with the surrounding cumulus cells ensures coordinated nuclear and cytoplasmic maturation of the oocyte, along with the accumulation of proteins stored within the oocyte in cytoplasmic lattices and endo-lysosomal vesicular assemblies. Study design, size, duration: This basic science study utilised a mouse model to assess proteomic changes across three oocyte competence models. Key proteins identified in mouse oocytes were also assessed in discarded immature human germinal vesicle (GV) oocytes and MII oocytes following rescue-IVM. Three oocyte maturation methods were tested: i) in vivo maturation, (ii) CAPA and (iii) standard IVM. In vivo maturation served as a positive control group, whereby metaphase II (MII) mature oocytes were collected from mice stimulated with pregnant mare serum gonadotropin (PMSG) and triggered with human chorionic gonadotropin (hCG), simulating full ovarian stimulation. For the in vitro maturation groups, immature cumulus oocyte complexes (COCs) were collected from mildly stimulated (23 hr PMSG) mice. For the standard IVM group, immature COCs were matured in media containing amphiregulin and epiregulin for 18 hours. For the CAPA group, COCs were held for 24 hours in pre-IVM conditions in the presence of c-type natriuretic peptide (CNP), oestradiol, insulin and follicle stimulating hormone (FSH), and then matured via IVM in media containing FSH, amphiregulin and epiregulin. Four biological replicates were performed for mouse proteomics experiments, three biological replicates performed for mouse immunocytochemistry experiments and six replicates were performed for embryology experiments. Participants/materials, settings, methods: Four to six-week-old C57BL/6JAusb mice were used for all mouse experiments. Embryology outcomes were used to confirm the variation in oocyte developmental competence between the three maturation groups. For the in vivo , CAPA and IVM groups, mature MII COCs were collected and separated into oocytes and cumulus cells. Oocytes and cumulus cells were subjected to mass spectrometry and bioinformatic analysis was performed using Proteome Discoverer and Ingenuity Pathway Analysis, with data validated by immunofluorescence. To assess conservation of proteins in human oocytes, 49 oocytes were collected from 36 patients following assisted reproduction technology (ART) cycles and subject to immunofluorescence. Rescue-IVM was also performed with half of the human oocyte cohort to obtain MII oocytes. Main results and the role of chance: Proteomic profiling identified around 1600 proteins in mouse oocytes and 3100 in mouse cumulus cells across all three treatment groups (at least 2 peptides per protein). Differential expression analysis and pattern analysis collectively revealed a signature of proteins that were consistently differentially expressed between in vivo and in vitro oocyte maturation systems (log2FC of ± 1 and a p-value ≤ 0.05). These subsets of proteins were mapped to biological processes including eukaryotic translation, autophagy and endocytosis pathways within oocytes. Orthogonal validation of clathrin, ribosomal protein L24 and eukaryotic initiation factor 2A supported the proteomic findings and expression was conserved in human oocytes. Changes in reactive oxygen species detoxification and serine biosynthesis were observed in mouse cumulus cells, with fluorescence intensity changes in ferredoxin-1 and phosphoglycerate dehydrogenase supporting the dysregulation of cumulus cell processes during in vitro maturation. Large scale data: The mass spectrometry data are available via ProteomeXchange with identifier PXD073269. Limitations, reasons for caution: The foundational mechanisms of oocyte developmental competence remain elusive, particularly in humans where MII oocytes are heterogenous in quality within the same stimulation cycle and patient. In this study, C57Bl6/J mice were used as the model species, allowing precise control over differing models of oocyte quality and capacity to analyse large numbers of oocytes. However, care is required when interpreting the significance of these findings in mice to mechanisms regulating human oocyte quality. Nonetheless, the in vivo stimulation and both IVM protocols used in this study are clinically relevant and developmentally matched. This study has also not addressed oocyte developmental competence in gonadotropin-free IVM oocytes, which is now a clinical reality. Wider implications of the findings: This study confirms that mouse oocytes, matured in vitro in two clinically relevant systems, show reduced developmental competence when compared to in vivo matured oocytes. Through examination of the global proteome in oocytes, molecular pathways including eukaryotic translation, autophagy and endocytosis were dysregulated in in vitro oocytes. Recent findings have revealed the critical role of these pathways to developmental competence in the context of in vivo development. In cumulus cells, changes in reactive oxygen species detoxification and serine biosynthesis were observed, adding to the extensive knowledge around metabolic activity in cumulus cells as a critical facet of oocyte quality. Combined, this data suggests that the necessary processes of protein storage and degradation in oocytes and metabolism in cumulus cells constitute important components of oocyte quality. These processes appear suboptimal in current IVM systems, providing a future research direction to optimise IVM protocols with consideration to these protein pathways. Study funding/competing interests: This study was funded by a National Health and Medical Research Council Investigator Fellowship (APP1023210) awarded to R.B.G. and by a gift from Open Philanthropy. The following competing interests are declared: R.B.G.is a consultant to Dioseve Inc.. L.E.W is a co-founder, shareholder, director and advisor of Jumpstart Fertility Inc.. L.E.W. is also an advisor and shareholder in EdenRoc Sciences, the parent company of Metro Biotech NSW and Metro Biotech, and in Life Biosciences LLC and its daughter companies. His UNSW Industry Scientia position is partly funded by Proto Axiom. All other authors have no competing interests to disclose.
Open AccessA proteomic signature of oocyte quality from models of varying oocyte developmental competence
Study question: Which proteins underpin oocyte developmental competence, as modelled by oocytes of variable competence matured in vivo , or matured in vitro under different conditions (capacitation in vitro maturation (CAPA) or standard in vitro maturation (IVM))? Summary answer: Significant differences in the global proteome were observed in both oocytes and their corresponding cumulus cells depending on the mode of oocyte maturation, with key variations in eukaryotic translation, autophagy and endocytosis pathways within oocytes, and changes in reactive oxygen species detoxification and serine biosynthesis in cumulus cells. What is known already: Within the ovarian follicle, mammalian oocytes must acquire the necessary molecular machinery to support successful fertilisation and embryonic development. Close contact with the surrounding cumulus cells ensures coordinated nuclear and cytoplasmic maturation of the oocyte, along with the accumulation of proteins stored within the oocyte in cytoplasmic lattices and endo-lysosomal vesicular assemblies. Study design, size, duration: This basic science study utilised a mouse model to assess proteomic changes across three oocyte competence models. Key proteins identified in mouse oocytes were also assessed in discarded immature human germinal vesicle (GV) oocytes and MII oocytes following rescue-IVM. Three oocyte maturation methods were tested: i) in vivo maturation, (ii) CAPA and (iii) standard IVM. In vivo maturation served as a positive control group, whereby metaphase II (MII) mature oocytes were collected from mice stimulated with pregnant mare serum gonadotropin (PMSG) and triggered with human chorionic gonadotropin (hCG), simulating full ovarian stimulation. For the in vitro maturation groups, immature cumulus oocyte complexes (COCs) were collected from mildly stimulated (23 hr PMSG) mice. For the standard IVM group, immature COCs were matured in media containing amphiregulin and epiregulin for 18 hours. For the CAPA group, COCs were held for 24 hours in pre-IVM conditions in the presence of c-type natriuretic peptide (CNP), oestradiol, insulin and follicle stimulating hormone (FSH), and then matured via IVM in media containing FSH, amphiregulin and epiregulin. Four biological replicates were performed for mouse proteomics experiments, three biological replicates performed for mouse immunocytochemistry experiments and six replicates were performed for embryology experiments. Participants/materials, settings, methods: Four to six-week-old C57BL/6JAusb mice were used for all mouse experiments. Embryology outcomes were used to confirm the variation in oocyte developmental competence between the three maturation groups. For the in vivo , CAPA and IVM groups, mature MII COCs were collected and separated into oocytes and cumulus cells. Oocytes and cumulus cells were subjected to mass spectrometry and bioinformatic analysis was performed using Proteome Discoverer and Ingenuity Pathway Analysis, with data validated by immunofluorescence. To assess conservation of proteins in human oocytes, 49 oocytes were collected from 36 patients following assisted reproduction technology (ART) cycles and subject to immunofluorescence. Rescue-IVM was also performed with half of the human oocyte cohort to obtain MII oocytes. Main results and the role of chance: Proteomic profiling identified around 1600 proteins in mouse oocytes and 3100 in mouse cumulus cells across all three treatment groups (at least 2 peptides per protein). Differential expression analysis and pattern analysis collectively revealed a signature of proteins that were consistently differentially expressed between in vivo and in vitro oocyte maturation systems (log2FC of ± 1 and a p-value ≤ 0.05). These subsets of proteins were mapped to biological processes including eukaryotic translation, autophagy and endocytosis pathways within oocytes. Orthogonal validation of clathrin, ribosomal protein L24 and eukaryotic initiation factor 2A supported the proteomic findings and expression was conserved in human oocytes. Changes in reactive oxygen species detoxification and serine biosynthesis were observed in mouse cumulus cells, with fluorescence intensity changes in ferredoxin-1 and phosphoglycerate dehydrogenase supporting the dysregulation of cumulus cell processes during in vitro maturation. Large scale data: The mass spectrometry data are available via ProteomeXchange with identifier PXD073269. Limitations, reasons for caution: The foundational mechanisms of oocyte developmental competence remain elusive, particularly in humans where MII oocytes are heterogenous in quality within the same stimulation cycle and patient. In this study, C57Bl6/J mice were used as the model species, allowing precise control over differing models of oocyte quality and capacity to analyse large numbers of oocytes. However, care is required when interpreting the significance of these findings in mice to mechanisms regulating human oocyte quality. Nonetheless, the in vivo stimulation and both IVM protocols used in this study are clinically relevant and developmentally matched. This study has also not addressed oocyte developmental competence in gonadotropin-free IVM oocytes, which is now a clinical reality. Wider implications of the findings: This study confirms that mouse oocytes, matured in vitro in two clinically relevant systems, show reduced developmental competence when compared to in vivo matured oocytes. Through examination of the global proteome in oocytes, molecular pathways including eukaryotic translation, autophagy and endocytosis were dysregulated in in vitro oocytes. Recent findings have revealed the critical role of these pathways to developmental competence in the context of in vivo development. In cumulus cells, changes in reactive oxygen species detoxification and serine biosynthesis were observed, adding to the extensive knowledge around metabolic activity in cumulus cells as a critical facet of oocyte quality. Combined, this data suggests that the necessary processes of protein storage and degradation in oocytes and metabolism in cumulus cells constitute important components of oocyte quality. These processes appear suboptimal in current IVM systems, providing a future research direction to optimise IVM protocols with consideration to these protein pathways. Study funding/competing interests: This study was funded by a National Health and Medical Research Council Investigator Fellowship (APP1023210) awarded to R.B.G. and by a gift from Open Philanthropy. The following competing interests are declared: R.B.G.is a consultant to Dioseve Inc.. L.E.W is a co-founder, shareholder, director and advisor of Jumpstart Fertility Inc.. L.E.W. is also an advisor and shareholder in EdenRoc Sciences, the parent company of Metro Biotech NSW and Metro Biotech, and in Life Biosciences LLC and its daughter companies. His UNSW Industry Scientia position is partly funded by Proto Axiom. All other authors have no competing interests to disclose.
- Open Access
- 21 August 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (10) , 2583-2618
Fertility protection during chemotherapy treatment by boosting the NAD(P)+ metabolome
Chemotherapy induced ovarian failure and infertility is an important concern in female cancer patients of reproductive age or younger, and non-invasive, pharmacological approaches to maintain ovarian function are urgently needed. Given the role of reduced nicotinamide adenine dinucleotide phosphate (NADPH) as an essential cofactor for drug detoxification, we sought to test whether boosting the NAD(P) + metabolome could protect ovarian function. We show that pharmacological or transgenic strategies to replenish the NAD + metabolome ameliorates chemotherapy induced female infertility in mice, as measured by oocyte yield, follicle health, and functional breeding trials. Importantly, treatment of a triple-negative breast cancer mouse model with the NAD + precursor nicotinamide mononucleotide (NMN) reduced tumour growth and did not impair the efficacy of chemotherapy drugs in vivo or in diverse cancer cell lines. Overall, these findings raise the possibility that NAD + precursors could be a non-invasive strategy for maintaining ovarian function in cancer patients, with potential benefits in cancer therapy.
- 21 August 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (10) , 2583-2618
Open AccessFertility protection during chemotherapy treatment by boosting the NAD(P)+ metabolome
Chemotherapy induced ovarian failure and infertility is an important concern in female cancer patients of reproductive age or younger, and non-invasive, pharmacological approaches to maintain ovarian function are urgently needed. Given the role of reduced nicotinamide adenine dinucleotide phosphate (NADPH) as an essential cofactor for drug detoxification, we sought to test whether boosting the NAD(P) + metabolome could protect ovarian function. We show that pharmacological or transgenic strategies to replenish the NAD + metabolome ameliorates chemotherapy induced female infertility in mice, as measured by oocyte yield, follicle health, and functional breeding trials. Importantly, treatment of a triple-negative breast cancer mouse model with the NAD + precursor nicotinamide mononucleotide (NMN) reduced tumour growth and did not impair the efficacy of chemotherapy drugs in vivo or in diverse cancer cell lines. Overall, these findings raise the possibility that NAD + precursors could be a non-invasive strategy for maintaining ovarian function in cancer patients, with potential benefits in cancer therapy.
- Open Access
Roles of TYRO3 Family Receptors in Germ Cell Development During Mouse Testis Formation
Structured Objective: To investigate the role of a potential SOX9 target gene, Tyro3 , along with its family members, Axl and Mertk (TAM family) in mouse testis development. Design: Experimental laboratory study. Setting: Research institute units. Subject(s): Embryonic day (E)11.5 Swiss mouse gonads for ex vivo gonad culture; Tyro3 knockout mouse embryos. Intervention(s): E11.5 Swiss mouse gonads were cultured in hanging droplets of 30 µL DMEM medium supplemented with 10% FBS and 1% antibiotic-antimycotic. A pair of gonads were treated with 20 μM of BMS-777607 or 30 μM of LDC1267 and an equivalent volume of the vehicle control DMSO. Main Outcome Measure(s): Immunofluorescence to measure morphological changes of ex vivo cultured gonads and in vivo Tyro3 mouse testes; qRT-PCR to measure gene expressions. Result(s): Inhibition of the TAM family in E11.5 ex vivo cultured male mouse gonads led to reduced germ cell numbers caused by reduced proliferation and increased apoptosis of the germ cells. Tyro3 knockout mice exhibited reduced expression levels of the germ cell genes Ddx4 , Dazl and Pou5f1 and increased expression levels of the Sertoli cell genes Sox9 and Amh at E12.5. However, by E14.5, the expression of Ddx4 , Dazl , Sox9 and Amh had returned to normal levels in Tyro3 knockout testes. Tyro3 knockout testes displayed normal morphology and structures during fetal testis development. Conclusion(s): TAM family members have redundant roles in regulating germ cell development during early testis development. Attestation Statement: Data regarding any of the subjects in the study has not been previously published unless specified. Data will be made available to the editors of the journal for review or query upon request. Data Sharing Statement: N/A Capsule: Inhibition of the TAM family led to loss of germ cells in fetal gonads and deletion of Tyro3 alone disturbed gene expressions of germ cells and Sertoli cells.
Open AccessRoles of TYRO3 Family Receptors in Germ Cell Development During Mouse Testis Formation
Structured Objective: To investigate the role of a potential SOX9 target gene, Tyro3 , along with its family members, Axl and Mertk (TAM family) in mouse testis development. Design: Experimental laboratory study. Setting: Research institute units. Subject(s): Embryonic day (E)11.5 Swiss mouse gonads for ex vivo gonad culture; Tyro3 knockout mouse embryos. Intervention(s): E11.5 Swiss mouse gonads were cultured in hanging droplets of 30 µL DMEM medium supplemented with 10% FBS and 1% antibiotic-antimycotic. A pair of gonads were treated with 20 μM of BMS-777607 or 30 μM of LDC1267 and an equivalent volume of the vehicle control DMSO. Main Outcome Measure(s): Immunofluorescence to measure morphological changes of ex vivo cultured gonads and in vivo Tyro3 mouse testes; qRT-PCR to measure gene expressions. Result(s): Inhibition of the TAM family in E11.5 ex vivo cultured male mouse gonads led to reduced germ cell numbers caused by reduced proliferation and increased apoptosis of the germ cells. Tyro3 knockout mice exhibited reduced expression levels of the germ cell genes Ddx4 , Dazl and Pou5f1 and increased expression levels of the Sertoli cell genes Sox9 and Amh at E12.5. However, by E14.5, the expression of Ddx4 , Dazl , Sox9 and Amh had returned to normal levels in Tyro3 knockout testes. Tyro3 knockout testes displayed normal morphology and structures during fetal testis development. Conclusion(s): TAM family members have redundant roles in regulating germ cell development during early testis development. Attestation Statement: Data regarding any of the subjects in the study has not been previously published unless specified. Data will be made available to the editors of the journal for review or query upon request. Data Sharing Statement: N/A Capsule: Inhibition of the TAM family led to loss of germ cells in fetal gonads and deletion of Tyro3 alone disturbed gene expressions of germ cells and Sertoli cells.
- Open Access
- 13 February 2024
- Published by CSIRO Publishing in Reproduction, Fertility and Development
- Vol. 36 (4)
Recent advances in reproductive research in Australia and New Zealand: highlights from the Annual Meeting of the Society for Reproductive Biology, 2022
In 2022, the Society for Reproductive Biology came together in Christchurch New Zealand (NZ), for its first face-to-face meeting since the global COVID-19 pandemic. The meeting showcased recent advancements in reproductive research across a diverse range of themes relevant to human health and fertility, exotic species conservation, and agricultural breeding practices. Here, we highlight the key advances presented across the main themes of the meeting, including advances in addressing opportunities and challenges in reproductive health related to First Nations people in Australia and NZ; increasing conservation success of exotic species, including ethical management of invasive species; improvements in our understanding of developmental biology, specifically seminal fluid signalling, ovarian development and effects of environmental impacts such as endocrine-disrupting chemicals; and leveraging scientific breakthroughs in reproductive engineering to drive solutions for fertility, including in assisted reproductive technologies in humans and agricultural industries, and for regenerative medicine.
- 13 February 2024
- Published by CSIRO Publishing in Reproduction, Fertility and Development
- Vol. 36 (4)
Open AccessRecent advances in reproductive research in Australia and New Zealand: highlights from the Annual Meeting of the Society for Reproductive Biology, 2022
In 2022, the Society for Reproductive Biology came together in Christchurch New Zealand (NZ), for its first face-to-face meeting since the global COVID-19 pandemic. The meeting showcased recent advancements in reproductive research across a diverse range of themes relevant to human health and fertility, exotic species conservation, and agricultural breeding practices. Here, we highlight the key advances presented across the main themes of the meeting, including advances in addressing opportunities and challenges in reproductive health related to First Nations people in Australia and NZ; increasing conservation success of exotic species, including ethical management of invasive species; improvements in our understanding of developmental biology, specifically seminal fluid signalling, ovarian development and effects of environmental impacts such as endocrine-disrupting chemicals; and leveraging scientific breakthroughs in reproductive engineering to drive solutions for fertility, including in assisted reproductive technologies in humans and agricultural industries, and for regenerative medicine.
- 9 October 2023
- Published by Wiley in Molecular Reproduction and Development
- Vol. 90 (10-11) , 773
A strong foundation for the next generation
- 9 October 2023
- Published by Wiley in Molecular Reproduction and Development
- Vol. 90 (10-11) , 773
A strong foundation for the next generation
- 23 August 2023
- Published by Elsevier in Trends in Biotechnology
- Vol. 42 (2) , 168-178
Making human eggs in a dish: are we close?
- 23 August 2023
- Published by Elsevier in Trends in Biotechnology
- Vol. 42 (2) , 168-178
Making human eggs in a dish: are we close?
- 5 April 2023
- Published by Springer Nature in Nature Reviews Urology
- Vol. 20 (7) , 434-451
Genetic control of typical and atypical sex development
Sex development relies on the sex-specific action of gene networks to differentiate the bipotential gonads of the growing fetus into testis or ovaries, followed by the differentiation of internal and external genitalia depending on the presence or absence of hormones. Differences in sex development (DSD) arise from congenital alterations during any of these processes, and are classified depending on sex chromosomal constitution as sex chromosome DSD, 46,XY DSD or 46,XX DSD. Understanding the genetics and embryology of typical and atypical sex development is essential for diagnosing, treating and managing DSD. Advances have been made in understanding the genetic causes of DSD over the past 10 years, especially for 46,XY DSD. Additional information is required to better understand ovarian and female development and to identify further genetic causes of 46,XX DSD, besides congenital adrenal hyperplasia. Ongoing research is focused on the discovery of further genes related to typical and atypical sex development and, therefore, on improving diagnosis of DSD.
- 5 April 2023
- Published by Springer Nature in Nature Reviews Urology
- Vol. 20 (7) , 434-451
Genetic control of typical and atypical sex development
Sex development relies on the sex-specific action of gene networks to differentiate the bipotential gonads of the growing fetus into testis or ovaries, followed by the differentiation of internal and external genitalia depending on the presence or absence of hormones. Differences in sex development (DSD) arise from congenital alterations during any of these processes, and are classified depending on sex chromosomal constitution as sex chromosome DSD, 46,XY DSD or 46,XX DSD. Understanding the genetics and embryology of typical and atypical sex development is essential for diagnosing, treating and managing DSD. Advances have been made in understanding the genetic causes of DSD over the past 10 years, especially for 46,XY DSD. Additional information is required to better understand ovarian and female development and to identify further genetic causes of 46,XX DSD, besides congenital adrenal hyperplasia. Ongoing research is focused on the discovery of further genes related to typical and atypical sex development and, therefore, on improving diagnosis of DSD.
- 14 February 2023
- Published by The Endocrine Society in Endocrinology
- Vol. 164 (5)
Somatic FGFR2 is Required for Germ Cell Maintenance in the Mouse Ovary
During sex determination in the mouse, Fibroblast growth factor 9 (FGF9) signals through the fibroblast growth factor receptor 2c isoform (FGFR2c) to trigger Sertoli cell and testis development from 11.5 days post coitum (dpc). In the XX gonad, the FOXL2 and WNT4/RSPO1 pathways drive granulosa cell and ovarian development. The function of FGFR2 in the developing ovary, and whether FGFR2 is required in the testis after sex determination is not clear. In fetal mouse gonads from 12.5 dpc, FGFR2 shows sexually dimorphic expression. In XX gonads, FGFR2c is co-expressed with FOXL2 in pre-granulosa cells, whereas XY gonads show FGFR2b expression in germ cells. Deletion of Fgfr2c in XX mice led to a marked decrease/absence of germ cells by 13.5 dpc in the ovary. This indicates that FGFR2c in the somatic pre-granulosa cells is required for the maintenance of germ cells. Surprisingly, on the Fgfr2c-/- background, the germ cell phenotype could be rescued by ablation of Foxl2, suggesting a novel mechanism whereby FGFR2 and FOXL2 act antagonistically during germ cell development. Consistent with low/absent FGFR2 expression in the Sertoli cells of 12.5 and 13.5 dpc XY gonads, XY AMH:Cre; Fgfr2flox/flox mice showed normal testis morphology and structures during fetal development and in adulthood. Thus, FGFR2 is not essential for maintaining Sertoli cell fate after sex determination. Combined, this data show that FGFR2 is not necessary for Sertoli cell function after sex determination but does play an important role in the ovary.
- 14 February 2023
- Published by The Endocrine Society in Endocrinology
- Vol. 164 (5)
Somatic FGFR2 is Required for Germ Cell Maintenance in the Mouse Ovary
During sex determination in the mouse, Fibroblast growth factor 9 (FGF9) signals through the fibroblast growth factor receptor 2c isoform (FGFR2c) to trigger Sertoli cell and testis development from 11.5 days post coitum (dpc). In the XX gonad, the FOXL2 and WNT4/RSPO1 pathways drive granulosa cell and ovarian development. The function of FGFR2 in the developing ovary, and whether FGFR2 is required in the testis after sex determination is not clear. In fetal mouse gonads from 12.5 dpc, FGFR2 shows sexually dimorphic expression. In XX gonads, FGFR2c is co-expressed with FOXL2 in pre-granulosa cells, whereas XY gonads show FGFR2b expression in germ cells. Deletion of Fgfr2c in XX mice led to a marked decrease/absence of germ cells by 13.5 dpc in the ovary. This indicates that FGFR2c in the somatic pre-granulosa cells is required for the maintenance of germ cells. Surprisingly, on the Fgfr2c-/- background, the germ cell phenotype could be rescued by ablation of Foxl2, suggesting a novel mechanism whereby FGFR2 and FOXL2 act antagonistically during germ cell development. Consistent with low/absent FGFR2 expression in the Sertoli cells of 12.5 and 13.5 dpc XY gonads, XY AMH:Cre; Fgfr2flox/flox mice showed normal testis morphology and structures during fetal development and in adulthood. Thus, FGFR2 is not essential for maintaining Sertoli cell fate after sex determination. Combined, this data show that FGFR2 is not necessary for Sertoli cell function after sex determination but does play an important role in the ovary.